Enzo Biochem (NYSE: ENZ) has announced its intention to voluntarily delist from the New York Stock Exchange and transfer to the OTCQX Best Market. The decision follows NYSE’s notice of non-compliance with continued listing standards regarding market capitalization, stockholder’s equity, and average closing stock price.
The delisting is expected to become effective around April 17, 2025, with OTCQX trading anticipated to commence on April 18, 2025. Shareholders will not need to exchange shares, and electronic trading should continue without material disruption. The company will maintain its SEC periodic reporting requirements.
Enzo Biochem operates through its Life Sciences division, focusing on labeling and detection technologies from DNA to whole cell analysis, offering products including antibodies, genomic probes, assays, biochemicals, and proteins.
Enzo…
